Skip to main content

Advertisement

SpringerLink
Log in

Therapy of immune neuropathies with intravenous immunoglobulins

  • Published:
Journal of Neurology Aims and scope Submit manuscript

An Erratum to this article was published on 01 February 2008

Abstract

Autoimmune-mediated disorders belong to the main causes of neuropathies worldwide. During recent years much progress has been achieved in the understanding of the underlying pathomechanisms, associated with implications for therapeutic approaches. Here we will briefly review the pathogenesis and discuss treatment options of the Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, multifocal motor neuropathy, and neuropathies associated with paraproteinemias. In most of these disease entities intravenous immunoglobulins play a major role as effective and safe treatment options.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ang CW, De Klerk MA, Endtz HP et al. (2001) Guillain-Barre syndrome- and Miller Fisher syndrome-associated Campylobacter jejuni lipopolysaccharides induce anti-GM(1) and anti-GQ(1b) antibodies in rabbits. Infect Immun 69:2462–2469

    Article  PubMed  CAS  Google Scholar 

  2. Azulay JP, Blin O, Pouget J et al. (1994) Intravenous immunoglobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: A double-blind, placebo-controlled study. Neurology 44:429–432

    PubMed  CAS  Google Scholar 

  3. Buchwald B, Ahangari R, Weishaupt A, Toyka KV (2002) Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barre syndrome. Ann Neurol 51:673–680

    Article  PubMed  CAS  Google Scholar 

  4. Comi G, Roveri L, Swan A et al. (2002) A randomised controlled trial of intravenous immunoglobulin in IgM paraprotein associated demyelinating neuropathy. J Neurol 249:1370–1377

    Article  PubMed  CAS  Google Scholar 

  5. Dalakas MC (2002) Mechanisms of action of IVIg and therapeutic considerations in the treatment of acute and chronic demyelinating neuropathies. Neurology 59:S13–S21

    PubMed  CAS  Google Scholar 

  6. Dalakas MC, Quarles RH, Farrer RG et al. (1996) A controlled study of intravenous immunoglobulin in demyelinating neuropathy with IgM gammopathy. Ann Neurol 40:792–795

    Article  PubMed  CAS  Google Scholar 

  7. Dyck PJ, Litchy WJ, Kratz KM et al. (1994) A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 36:838–845

    Article  PubMed  CAS  Google Scholar 

  8. Federico P, Zochodne DW, Hahn AF, Brown WF, Feasby TE (2000) Multifocal motor neuropathy improved by IVIg: randomized, double-blind, placebo-controlled study. Neurology 55:1256–1262

    PubMed  CAS  Google Scholar 

  9. Fujinami RS, Oldstone MBA (1985) Aminoacid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity. Science 230:1043–1045

    PubMed  CAS  Google Scholar 

  10. Gold R, Dalakas MC, Toyka KV (2003) Immunotherapy in autoimmune neuromuscular disorders. Lancet Neurology 2:22–32

    Article  PubMed  CAS  Google Scholar 

  11. Gorson KC, Ropper AH, Weinberg DH, Weinstein R (2002) Efficacy of intravenous immunoglobulin in patients with IgG monoclonal gammopathy and polyneuropathy. Arch Neurol 59:766–772

    Article  PubMed  Google Scholar 

  12. Hadden RD, Cornblath DR, Hughes RA et al. (1998) Electrophysiological classification of Guillain-Barre syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group. Ann Neurol 44:780–788

    Article  PubMed  CAS  Google Scholar 

  13. Hahn AF, Bolton CF, Zochodne D, Feasby TE (1996) Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy—A double-blind, placebo-controlled, cross-over study. Brain 119:1067–1077

    PubMed  Google Scholar 

  14. Hartung HP, Pollard JD, Harvey GK, Toyka KV (1995) Immunopathogenesis and treatment of the Guillain-Barré syndrome. Part I Muscle Nerve 18:154–164

    Article  PubMed  CAS  Google Scholar 

  15. Hughes R, Bensa S, Willison H et al. (2001) Randomized controlled trial of intravenous immunoglobulin versus oral prednisolone in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 50:195–201

    Article  PubMed  CAS  Google Scholar 

  16. Hughes RA, Hadden RD, Gregson NA, Smith KJ (1999) Pathogenesis of Guillain-Barre syndrome. J Neuroimmunol 100:74–97

    Article  PubMed  CAS  Google Scholar 

  17. Kieseier BC, Kiefer R, Gold R et al. (2004) Advances in understanding and treatment of immune-mediated disorders of the peripheral nervous system. Muscle Nerve 30:131–156

    Article  PubMed  CAS  Google Scholar 

  18. Koga M, Yuki N, Tai T, Hirata K (2001) Miller Fisher syndrome and Haemophilus influenzae infection. Neurology 57:686–691

    PubMed  CAS  Google Scholar 

  19. Korinthenberg R, Schessl J, Kirschner J, Monting JS (2005) Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barre syndrome: A randomized trial. Pediatrics 116:8–14

    Article  PubMed  Google Scholar 

  20. Lassmann H, Bruck W, Lucchinetti C (2001) Heterogeneity of multiple sclerosis pathogenesis: implications for diagnosis and therapy. Trends Mol Med 7:115–12

    Article  PubMed  CAS  Google Scholar 

  21. Leger JM, Chassande B, Musset L et al. (2001) Intravenous immunoglobulin therapy in multifocal motor neuropathy: a double-blind, placebo-controlled study. Brain 124:145–153

    Article  PubMed  CAS  Google Scholar 

  22. Mariette X, Chastang C, Clavelou P et al. (1997) A randomised clinical trial comparing interferon-alpha and intravenous immunoglobulin in polyneuropathy associated with monoclonal IgM. The IgM-associated Polyneuropathy Study Group. J Neurol Neurosurg Psychiatry 63:28–34

    PubMed  CAS  Google Scholar 

  23. Mendell JR, Barohn RJ, Freimer ML et al. (2001) Randomized controlled trial of IVIg in untreated chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 56:445–449

    PubMed  CAS  Google Scholar 

  24. Plasma Exchange/Sandoglobulin Guillain-Barre Syndrome Trial Group (1997) Comparison of plasma exchange, intravenous immunoglobulin, and plasma exchange followed by intravenous immunoglobulin in the treatment of Guillain-Barre syndrome. Lancet 349:225–230

    Article  Google Scholar 

  25. Raphael JC, Chevret S, Harboun M, Jars-Guincestre MC (2001) Intravenous immune globulins in patients with Guillain-Barre syndrome and contraindications to plasma exchange: 3 days versus 6 days. J Neurol Neurosurg Psych 71:235–238

    Article  CAS  Google Scholar 

  26. Renaud S, Gregor M, Fuhr P et al. (2003) Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve 27:611–615

    Article  PubMed  CAS  Google Scholar 

  27. Ruegg SJ, Fuhr P, Steck AJ (2004) Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg. Neurology 63:2178–2179

    PubMed  Google Scholar 

  28. Shevach EM (2002) CD4+ CD25+ suppressor T cells: more questions than answers. Nat Rev Immunol 2:389–400

    PubMed  CAS  Google Scholar 

  29. Simmons Z, Bromberg MB, Feldman EL, Blaivas M (1993) Polyneuropathy associated with IgA monoclonal gammopathy of undetermined significance. Muscle Nerve 16:77–83

    Article  PubMed  CAS  Google Scholar 

  30. Stangel M, Toyka KV, Gold R (1999) Mechanisms of high-dose intravenous immunoglobulins in demyelinating diseases. Arch Neurol 56:661–663

    Article  PubMed  CAS  Google Scholar 

  31. Van den Berg LH, Kerkhoff H, Oey PL et al. (1995) Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 59:248–252

    PubMed  CAS  Google Scholar 

  32. van der Meche FGA, Schmitz PIM, and the Dutch Guillain-Barre study group (1992) A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barre syndrome. N Engl J Med 326:1123–1129

    Article  PubMed  CAS  Google Scholar 

  33. van Doorn PA, Brand A, Strengers PF, Meulstee J, Vermeulen M (1990) High-dose intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, crossover study (see comments). Neurology 40:209–212

    PubMed  CAS  Google Scholar 

  34. van Doorn PA, Ruts L (2004) Treatment of chronic inflammatory demyelinating polyneuropathy. Curr Opin Neurol 17:607–613

    Article  PubMed  CAS  Google Scholar 

  35. Van Koningsveld R, Schmitz PIM, van der Meche FGA et al. (2004) Effect of methylprednisolone when added to standard treatment with intravenous immunoglobulin for Guillain-Barre syndrome: randomised trial. Lancet 363:192–196

    Article  PubMed  CAS  Google Scholar 

  36. Vermeulen M, van Doorn PA, Brand A et al. (1993) Intravenous immunoglobulin treatment in patients with chronic inflammatory demyelinating polyneuropathy: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 56:36–39

    Article  PubMed  CAS  Google Scholar 

  37. Visser LH, van der Meche FG, van Doorn PA et al. (1995) Guillain-Barre syndrome without sensory loss (acute motor neuropathy). A subgroup with specific clinical, electrodiagnostic and laboratory features. Dutch Guillain-Barre Study Group. Brain 118:841–847

    PubMed  Google Scholar 

  38. Willison HJ, Yuki N (2002) Peripheral neuropathies and anti-glycolipid antibodies. Brain 125:2591–2625

    Article  PubMed  Google Scholar 

  39. Yuki N (1997) Molecular mimicry between gangliosides and lipopolysaccharides of Campylobacter jejuni isolated from patients with Guillain-Barre syndrome and Miller Fisher syndrome. J Infect Dis 176:S150–S153

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute for MS research, Waldweg 33, 37073, Göttingen, Germany

    Ralf Gold

  2. Department of Neurology, Heinrich-Heine-University, Düsseldorf, Germany

    Bernd C. Kieseier

Authors
  1. Ralf Gold
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bernd C. Kieseier
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ralf Gold.

Additional information

An erratum to this article is available at http://dx.doi.org/10.1007/s00415-008-0881-z.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gold, R., Kieseier, B.C. Therapy of immune neuropathies with intravenous immunoglobulins. J Neurol 253 (Suppl 5), v59–v63 (2006). https://doi.org/10.1007/s00415-006-5008-9

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-006-5008-9

Key words

Search

Navigation